Darifenacin is a selective muscarinic M3 receptor antagonist that reduces detrusor muscle contractility, used for the treatment of overactive bladder syndrome with reduced CNS side effects due to its M3 subtype selectivity. Simson Pharma's Darifenacin reference standard and impurities support stability-indicating testing for this urology-focused anticholinergic.
Simson Pharma Global Ltd. (UK) and Simson Pharma Global LLC (USA) supply high-quality Darifenacin Reference Standards, pharmacopoeial reference materials, and its related impurities to pharmaceutical manufacturers, CROs, analytical laboratories, universities, and regulatory organizations worldwide. To service the Europe and America market efficiently, Simson Pharma Limited has set up Simson Pharma Global Ltd. in United Kingdom and Simson Pharma Global LLC in USA respectively.